Placeholder Banner

Vonnie Estes to Receive 2017 Rosalind Franklin Award

June 14, 2017

The Biotechnology Innovation Organization (BIO) today announced that biotech industry veteran Vonnie Estes will receive the 4th annual Rosalind Franklin Award for Leadership in Industrial Biotechnology. The award will be presented on Tuesday July 25, 2017, during a lunch plenary session of the 2017 BIO World Congress on Industrial Biotechnology. The world’s largest industrial biotechnology and partnering event will be held July 23-26, 2017 at the Palais des congrès de Montréal in Montréal, Québec, Canada.

“Scientific discoveries only achieve positive impacts once they are successfully deployed throughout society, and that requires a deep network of people,” said Estes. “Throughout my career, I have focused on developing the supply chains necessary to commercialize biotechnology innovations, motivated by a passion to achieve sustainability in industry. I am honored to accept the Rosalind Franklin Award on behalf of the numerous colleagues who have shared that passion.”

Brent Erickson, executive vice president of BIO’s Industrial & Environmental Section, added, “Vonnie Estes is an accomplished industry leader with decades of experience commercializing industrial biotechnology innovations and developing emerging companies. She has held key leadership positions in companies, including DuPont, GranBio, Caribou Biosciences, Monsanto, and Syngenta. With this award, BIO hopes to honor Rosalind Franklin’s legacy by recognizing women who make lasting contributions to the field of biotechnology.”

The Award will again be sponsored by the Rosalind Franklin Society, whose goal is to support and showcase the careers of eminent women in science. “Rosalind Franklin made an important contribution to the discovery of the structure of DNA. Her work serves as an inspiration and model to female scientists. Throughout her distinguished career, Vonnie Estes has made numerous contributions to the commercial development of new biotechnologies, creating revolutionary products that are good for people and the planet,” said Rita R. Colwell, PhD, President of the Rosalind Franklin Society and Distinguished University Professor at the University of Maryland College Park and John Hopkins Bloomberg School of Public Health.

Rosalind Franklin conceived and captured Photograph 51 of the "B" form of DNA in 1952, while at King's College in London. This photograph, acquired through 100 hours of X-ray exposure from a machine Dr. Franklin herself refined, revealed the structure of DNA. The discovery of the structure of DNA was the single most important advance of modern biology. James Watson and Francis Crick, working at Cambridge University, used Photograph 51 as the basis for their famous model of DNA, which earned them a Nobel Prize in 1962. Though sometimes overlooked, Rosalind Franklin’s critical work and discovery in the field has allowed the biotechnology industry to become what it is today.

Vonnie Estes is currently an independent business consultant. She was most recently Vice President of Business Development at Caribou Biosciences, leading the company’s partnerships and business development activities in agricultural and industrial biotechnology. Prior to joining Caribou Biosciences, Vonnie Estes served as Managing Director for GranBio, where she oversaw the company’s continued expansion and growth across North America and was responsible for identifying and licensing new technologies, overseeing large capital investments and raising brand awareness. Vonnie Estes is a Board Director of Microvi Biotechnologies, a member of the Iteris ClearAg Advisory Council, a member of the Advisory Board of Agile BioFoundry, and a member of Biomass R&D Technical Advisory Committee at the US Office of Energy Efficiency and Renewable Energy. She formerly served on BIO’s Industrial & Environmental Section Governing Board.

Vonnie Estes is the 4th recipient honored with the annual Rosalind Franklin Award; past recipients include:

  • Anna Rath, President and CEO of NexSteppe, in 2016;

  • Dr. Jennifer Holmgren, CEO of LanzaTech, in 2015; and

  • Dr. Debbie S. Yaver, Director of Expression Technology, Genomics and Bioinformatics at Novozymes, in 2014.

 

All programs at the 2017 BIO World Congress on Industrial Biotechnology are open to members of the media. Complimentary media registration is available to editors and reporters working full time for print, broadcast or web publications with valid press credentials.

 

For more information on the conference please visit https://www.bio.org/events/bio-world-congress. For assistance, please contact [email protected].

 

Discover More
BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…
“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…